Sekar Seshagiri is a world leader in the field of genomics and drug discovery. He is founder of Venbio Sciences, a company focused on studying venomous animals and anti-venom development. He recently served as the CEO and CSO of AntlerA therapeutics, a regenerative medicines company, that was acquired by Roche. At AntlerA he developed a novel antibody drug, now in Phase 3 clinical trials for treating diabetic macular edema, that was acquired by Eyebio/Merck. Sekar is Chief of Genomics at MedGenome Inc. USA, and also servers on multiple scientific advisory boards. Prior to this, he spent over 20 years at Genentech where he was a Staff Scientist and Associate Director. During his tenure at Genentech, he established a state-of-the-art genomics laboratory where he conducted research in cancer and cell signaling areas to support drug discovery and development. He published the first high quality reference genome of the medically important Indian Cobra in Nature Genetics. He has authored and co-authored over 100 articles in peer-reviewed journals including Nature, Nature Genetics, Science, and Cancer Cell.